Bodo Haas

1.4k total citations
29 papers, 1.1k citations indexed

About

Bodo Haas is a scholar working on Physiology, Molecular Biology and Epidemiology. According to data from OpenAlex, Bodo Haas has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 9 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Bodo Haas's work include Adipose Tissue and Metabolism (9 papers), Adipokines, Inflammation, and Metabolic Diseases (6 papers) and Glioma Diagnosis and Treatment (3 papers). Bodo Haas is often cited by papers focused on Adipose Tissue and Metabolism (9 papers), Adipokines, Inflammation, and Metabolic Diseases (6 papers) and Glioma Diagnosis and Treatment (3 papers). Bodo Haas collaborates with scholars based in Germany, United States and Switzerland. Bodo Haas's co-authors include Alexander Pfeifer, Niels Eckstein, P. Mayer, Franziska Siegel, Gunter Meister, Holger Fröhlich, Yong Chen, Reinhard Fässler, Claus Hellerbrand and Ramin Massoumi and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and The Journal of Cell Biology.

In The Last Decade

Bodo Haas

27 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bodo Haas Germany 13 522 391 229 196 152 29 1.1k
Timothy A. Hoffman United States 11 652 1.2× 470 1.2× 158 0.7× 219 1.1× 96 0.6× 11 1.4k
Jeremy DeRicco United States 10 575 1.1× 440 1.1× 116 0.5× 203 1.0× 94 0.6× 11 1.3k
De‐Long Hao China 19 702 1.3× 302 0.8× 221 1.0× 222 1.1× 104 0.7× 37 1.4k
Nikolay Patrushev United States 14 1.0k 1.9× 484 1.2× 201 0.9× 203 1.0× 105 0.7× 15 1.7k
Panjamaporn Sangwung United States 18 750 1.4× 258 0.7× 164 0.7× 234 1.2× 68 0.4× 23 1.3k
Jun Hao China 23 629 1.2× 167 0.4× 176 0.8× 159 0.8× 107 0.7× 57 1.3k
Yang Qiu China 14 396 0.8× 307 0.8× 121 0.5× 179 0.9× 137 0.9× 43 809
Emmani B. M. Nascimento Netherlands 18 532 1.0× 610 1.6× 85 0.4× 321 1.6× 149 1.0× 30 1.2k
Reiko Matsui United States 23 822 1.6× 377 1.0× 116 0.5× 119 0.6× 84 0.6× 48 1.5k
Diana M. Willmes Germany 14 839 1.6× 380 1.0× 368 1.6× 391 2.0× 105 0.7× 17 1.5k

Countries citing papers authored by Bodo Haas

Since Specialization
Citations

This map shows the geographic impact of Bodo Haas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bodo Haas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bodo Haas more than expected).

Fields of papers citing papers by Bodo Haas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bodo Haas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bodo Haas. The network helps show where Bodo Haas may publish in the future.

Co-authorship network of co-authors of Bodo Haas

This figure shows the co-authorship network connecting the top 25 collaborators of Bodo Haas. A scholar is included among the top collaborators of Bodo Haas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bodo Haas. Bodo Haas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Кirilov, Кiril, Maria Ponticelli, Toni Kühl, et al.. (2025). Neurotensin(8-13) analogs targeting NTS1 and NTS2 receptors: A comparative in vitro and molecular modeling study. Current Research in Biotechnology. 9. 100298–100298.
2.
Felter, Susan P., David J. Ponting, Robert Thomas, et al.. (2025). Evaluating the lifetime cumulative dose as a basis for carcinogenic potency of nitrosamines – a key tenet underpinning less-than-lifetime approaches for establishing acceptable intake limits. Regulatory Toxicology and Pharmacology. 162. 105903–105903.
3.
Haas, Bodo, et al.. (2025). Apoptotic and senolytic effects of hERG/Eag1 channel blockers in combination with temozolomide in human glioblastoma cells. Naunyn-Schmiedeberg s Archives of Pharmacology. 398(9). 12267–12278. 1 indexed citations
4.
Haas, Bodo, et al.. (2024). Sulfonylureas exert antidiabetic action on adipocytes by inhibition of PPARγ serine 273 phosphorylation. Molecular Metabolism. 85. 101956–101956. 4 indexed citations
5.
Kruhlak, Naomi L., Marianne Schmidt, Roland Froetschl, et al.. (2024). Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regulatory Toxicology and Pharmacology. 150. 105640–105640. 39 indexed citations
6.
Haas, Bodo, et al.. (2020). Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. Journal of Cancer Research and Clinical Oncology. 147(3). 779–792. 5 indexed citations
7.
Kaina, Bernd, et al.. (2020). Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. International Journal of Molecular Sciences. 21(19). 7006–7006. 12 indexed citations
8.
Haas, Bodo, Julia Walther, Gabriele Röhn, et al.. (2018). Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell International. 18(1). 69–69. 31 indexed citations
9.
Haas, Bodo, Konstantin Weber‐Lassalle, Roland Frötschl, & Niels Eckstein. (2016). Is sunitinib a Narrow Therapeutic Index Drug? – A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues. Regulatory Toxicology and Pharmacology. 77. 25–34. 7 indexed citations
10.
Haas, Bodo, et al.. (2015). A novel crosstalk between Alk7 and cGMP signaling differentially regulates brown adipocyte function. Molecular Metabolism. 4(8). 576–583. 10 indexed citations
11.
Eckstein, Niels, et al.. (2014). Systemic therapy of Cushing’s syndrome. Orphanet Journal of Rare Diseases. 9(1). 122–122. 10 indexed citations
12.
Haas, Bodo, et al.. (2014). Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutrition and Diabetes. 4(11). e143–e143. 83 indexed citations
13.
Eckstein, Niels, et al.. (2014). Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. Journal of Experimental & Clinical Cancer Research. 33(1). 15–15. 32 indexed citations
14.
Eckstein, Niels & Bodo Haas. (2014). Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancer. European Journal of Clinical Pharmacology. 70(7). 791–798. 19 indexed citations
15.
Chen, Yong, Franziska Siegel, Bodo Haas, et al.. (2013). miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. Nature Communications. 4(1). 1769–1769. 236 indexed citations
16.
Haas, Bodo, et al.. (2013). Analysis of cGMP Signaling in Adipocytes. Methods in molecular biology. 1020. 175–192. 7 indexed citations
17.
Haas, Bodo, et al.. (2012). Targeting adipose tissue. Diabetology & Metabolic Syndrome. 4(1). 43–43. 31 indexed citations
18.
Mayer, P., et al.. (2011). Glitazone‐like action of glimepiride and glibenclamide in primary human adipocytes. Diabetes Obesity and Metabolism. 13(9). 791–799. 7 indexed citations
19.
Massoumi, Ramin, Silke Kuphal, Claus Hellerbrand, et al.. (2009). Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. The Journal of Cell Biology. 184(1). i1–i1. 7 indexed citations
20.
Scherer, Michael, et al.. (1998). Glykosaminoglykane als Marker für die posttraumatische Gonarthrose?. Der Chirurg. 69(1). 82–90. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy A. Hoffman Breakdown of academic impact, for papers by Jeremy DeRicco Breakdown of academic impact, for papers by De‐Long Hao Breakdown of academic impact, for papers by Nikolay Patrushev Breakdown of academic impact, for papers by Panjamaporn Sangwung Breakdown of academic impact, for papers by Jun Hao Breakdown of academic impact, for papers by Yang Qiu Breakdown of academic impact, for papers by Emmani B. M. Nascimento Breakdown of academic impact, for papers by Reiko Matsui Breakdown of academic impact, for papers by Diana M. Willmes
Rankless by CCL
2026